LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Fechado

SetorSaúde

2.63 3.95

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.45

Máximo

2.66

Indicadores-chave
By Trading Economics
Rendimento	-27M -17M
EPS	-0.125
Margem de lucro	-2,366.017
Funcionários	23
EBITDA	-5.5M -18M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+109.84% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-19M 464M
Abertura anterior	-1.32
Fecho anterior	2.63

Sentimento de Notícias

By Acuity

50%

156 / 344 Ranking em Healthcare

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de mai. de 2026, 22:47 UTC

Ganhos

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 de mai. de 2026, 20:45 UTC

Ganhos

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 de mai. de 2026, 23:31 UTC

Conversa de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 de mai. de 2026, 22:37 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 de mai. de 2026, 21:12 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 de mai. de 2026, 21:00 UTC

Ganhos

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 de mai. de 2026, 20:57 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:55 UTC

Ganhos

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

28 de mai. de 2026, 20:48 UTC

Ações em Alta

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 de mai. de 2026, 20:34 UTC

Ganhos

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 de mai. de 2026, 20:31 UTC

Ganhos

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 de mai. de 2026, 20:28 UTC

Ganhos

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 de mai. de 2026, 20:26 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Membership Fees $1.37B

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Net Sales $69.15B

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

109.84% parte superior

Previsão para 12 meses

Média 5.33 USD 109.84%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

156 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.